<SEC-DOCUMENT>0001104659-11-052922.txt : 20110922
<SEC-HEADER>0001104659-11-052922.hdr.sgml : 20110922
<ACCEPTANCE-DATETIME>20110922161621
ACCESSION NUMBER:		0001104659-11-052922
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20110916
ITEM INFORMATION:		Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20110922
DATE AS OF CHANGE:		20110922

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50626
		FILM NUMBER:		111103215

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a11-26858_18k.htm
<DESCRIPTION>8-K
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<div style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 3.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED STATES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Washington, D.C. 20549</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM&nbsp;8-K</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">CURRENT REPORT</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">Pursuant to Section&nbsp;13 or 15(d)</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">of the Securities Exchange Act of 1934</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date of Report (Date of earliest event reported):&#160; <b>September&nbsp;16, 2011</b></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">CYCLACEL PHARMACEUTICALS,&nbsp;INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact name of registrant as specified in its charter)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Delaware</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">0-50626</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">91-1707622</font></b></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(State or other jurisdiction<br>   of incorporation)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Commission File Number)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(IRS Employer<br>   Identification No.)</font></p>    </td>   </tr>  </table>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">200 Connell Drive, Suite&nbsp;1500<br> Berkeley Heights, NJ 07922</font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">  <br>  </font></b><font size="2" style="font-size:10.0pt;">(Address of principal executive offices and zip code)</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Registrant&#146;s telephone number, including area code:<b> (908) 517-7330</b></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Former Name or Former Address, if Changed Since Last Report)</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Check the appropriate box below if the Form&nbsp;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i>see </i>General Instruction A.2. below):</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="2" style="font-size:10.0pt;">&#160;&#160;&#160; Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="2" style="font-size:10.0pt;">&#160;&#160;&#160; Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12) </font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="2" style="font-size:10.0pt;">&#160;&#160;&#160; Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17 CFR 240.14d-2(b)) </font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="2" style="font-size:10.0pt;">&#160;&#160;&#160; Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c)) </font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="border-bottom:solid windowtext 3.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\jkarthi\11-26858-1\task4878519\26858-1-ba.htm',USER='105429',CD='Sep 22 08:57 2011' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item&nbsp;3.01&nbsp;&nbsp;&nbsp;&nbsp;Notice of Delisting or Failure to Satisfy a Continued Listing Rule&nbsp;or Standard; Transfer or Listing.</font></b></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On September&nbsp;16, 2011, Cyclacel Pharmaceuticals,&nbsp;Inc. (the &#147;<b><u style="font-weight:bold;">Company</u></b>&#148;) received a deficiency letter from The NASDAQ Stock Market LLC (&#147;<b><u style="font-weight:bold;">NASDAQ</u></b>&#148;) notifying the Company that for the last 30 consecutive business days the bid price of the Company&#146;s securities had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of NASDAQ set forth in Listing Rule&nbsp;5450(a)(1)&nbsp;(the &#147;<b><u style="font-weight:bold;">Rule</u></b>&#148;).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In accordance with Listing Rule&nbsp;5810(c)(3)(A), the Company has 180 calendar days, or until March&nbsp;14, 2012, to regain compliance with the Rule. To regain compliance, the closing bid price of the Company&#146;s securities must be at least $1.00 per share for a minimum ten consecutive business days. If the Company does not regain compliance with the Rule&nbsp;by March&nbsp;14, 2012, NASDAQ will issue a delisting letter. At that time, the Company may request a hearing before a Listing Qualification Panel, which will stay the delisting. Alternatively, the Company may transfer its securities to The NASDAQ Capital Market and be eligible to an additional 180-day period to regain compliance if it meets the initial listing standards, with the exception of bid price, for The NASDAQ Capital Market.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On September&nbsp;22, 2011, the Company issued a press release announcing its receipt of NASDAQ&#146;s deficiency letter. A copy of the press release is being furnished as Exhibit&nbsp;99.1 to this report and is incorporated herein by reference.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item&nbsp;9.01&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.</font></b></p>
<p style="margin:0in 0in .0001pt 27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)&nbsp;Exhibits:</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following exhibit is furnished herewith:</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1 &nbsp;&nbsp;Press release, dated September&nbsp;22, 2011</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="PB_2_053056_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\jkarthi\11-26858-1\task4878519\26858-1-ba.htm',USER='105429',CD='Sep 22 08:57 2011' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="51%" valign="top" style="padding:0in 0in 0in 0in;width:51.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:48.08%;">
<p style="margin:0in 0in .0001pt 20.9pt;text-indent:-10.1pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CYCLACEL PHARMACEUTICALS,&nbsp;INC.</font></b></p>    </td>   </tr>
<tr>
<td width="51%" valign="top" style="padding:0in 0in 0in 0in;width:51.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="48%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:48.08%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="51%" valign="top" style="padding:0in 0in 0in 0in;width:51.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="48%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:48.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="51%" valign="top" style="padding:0in 0in 0in 0in;width:51.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="41%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:41.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Paul McBarron</font></p>    </td>   </tr>
<tr>
<td width="51%" valign="top" style="padding:0in 0in 0in 0in;width:51.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="41%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:41.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Paul   McBarron</font></p>    </td>   </tr>
<tr>
<td width="51%" valign="top" style="padding:0in 0in 0in 0in;width:51.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Executive   Vice President&#151;Finance,</font></p>    </td>   </tr>
<tr>
<td width="51%" valign="top" style="padding:0in 0in 0in 0in;width:51.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief   Financial Officer and</font></p>    </td>   </tr>
<tr>
<td width="51%" valign="top" style="padding:0in 0in 0in 0in;width:51.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="41%" valign="top" style="padding:0in 0in 0in 0in;width:41.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief   Operating Officer</font></p>    </td>   </tr>
<tr>
<td width="51%" valign="top" style="padding:0in 0in 0in 0in;width:51.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="48%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:48.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="51%" valign="top" style="padding:0in 0in 0in 0in;width:51.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:   September&nbsp;22, 2011</font></p>    </td>
<td width="48%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:48.08%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3<a name="PB_3_053437_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\jkarthi\11-26858-1\task4878519\26858-1-ba.htm',USER='105429',CD='Sep 22 08:57 2011' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a11-26858_1ex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 99.1</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="54%" valign="top" style="padding:0in 0in 0in 0in;width:54.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><img width="174" height="65" src="g268581mmi001.jpg"></font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="41%" style="padding:0in 0in 0in 0in;width:41.92%;">
<p align="right" style="margin:0in .25in .0001pt 0in;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cyclacel   Pharmaceuticals,&nbsp;Inc.</font></p>    </td>   </tr>  </table>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="576" height="26" src="g268581mmi002.jpg"></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CYCLACEL PHARMACEUTICALS </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">RECEIVES DEFICIENCY NOTICE FROM</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NASDAQ GLOBAL SELECT MARKET</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Berkeley Heights, NJ, September&nbsp;22, 2011 </font></b><font size="2" style="font-size:10.0pt;">&#151; Cyclacel Pharmaceuticals,&nbsp;Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the Company), today announced that it received a Nasdaq Staff Deficiency Letter on September&nbsp;16, 2011 indicating that the Company fails to comply with the minimum bid price requirement for continued listing set forth in Marketplace Rule&nbsp;5450(a)(1). The letter gives Cyclacel notice that bid price of the Company&#146;s common stock has closed under $1.00 for the last 30 business days.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Nasdaq notice has no effect on the listing of the Company&#146;s common stock at this time.&#160; Pursuant to Nasdaq Marketplace Rule&nbsp;5810(c)(3)(A), the Company has an initial period of 180 calendar days, or until March&nbsp;14, 2012, to regain compliance. The letter states the Nasdaq staff will provide written notification that the Company has achieved compliance with Rule&nbsp;5450(a)(1)&nbsp;if at any time before March&nbsp;14, 2012, the bid price of the Company&#146;s common stock closes at $1.00 per share or more for a minimum of 10 consecutive business days.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If the Company cannot demonstrate compliance with Rule&nbsp;5450(a)(1)&nbsp;by March&nbsp;14, 2012, it may transfer its listing to The Nasdaq Capital Market if it meets the initial listing criteria set forth in Nasdaq Marketplace Rule&nbsp;5505, except for the bid price requirement.&#160; In that case, it may have an additional 180 calendar day compliance period in which to comply with the minimum bid price requirement. The Company currently meets these initial listing criteria.&#160; Otherwise, the Nasdaq staff may begin the process to have the Company&#146;s securities delisted.&#160; At that time, the Company may appeal the Nasdaq staff&#146;s determination to delist its securities to a Listing Qualifications Panel.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About Cyclacel Pharmaceuticals,&nbsp;Inc.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cyclacel is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases.&#160; Sapacitabine (CYC682), a cell cycle modulating nucleoside analog, is in Phase 3 development for the front-line treatment of acute myeloid leukemia in the elderly and Phase 2 studies for myelodysplastic syndromes, lung cancer and chronic lymphocytic leukemia.&#160;&#160; Seliciclib (CYC202 or R-roscovitine), a CDK (cyclin dependent kinase) inhibitor, is in Phase 2 studies for the treatment of lung cancer and nasopharyngeal cancer and in a Phase 1 trial in combination with sapacitabine.&#160; Cyclacel&#146;s ALIGN Pharmaceuticals subsidiary markets directly in the U.S. Xclair</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font><font size="2" style="font-size:10.0pt;">&#160;Cream for radiation dermatitis, Numoisyn</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font><font size="2" style="font-size:10.0pt;">&#160;Liquid and Numoisyn</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font><font size="2" style="font-size:10.0pt;">&#160;Lozenges for xerostomia.&#160; Cyclacel&#146;s strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates.&#160; Please visit www.cyclacel.com for additional information.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Forward-looking Statements</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety, and intended utilization of Cyclacel&#146;s product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its products, the risks associated with reliance on outside financing to meet capital </font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">x</font></p>    </td>
<td width="95%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:95.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">200 Connell Drive, Suite&nbsp;1500, Berkeley   Heights, NJ&nbsp; 07922 USA T: +1 (908) 517 7330 F: +1 (866) 271 3466</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>    </td>
<td width="95%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:95.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dundee Technopole, James Lindsay Place,   Dundee, DD1 5JJ, UK Tel +44 1382 206 062 Fax +44 1382 206 067</font></p>    </td>   </tr>
<tr>
<td width="27%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:27.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="72%" valign="top" style="padding:0in 0in 0in 0in;width:72.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">www.cyclacel.com &#151;   info@cyclacel.com</font></p>    </td>   </tr>
<tr height="0">
<td width="31" style="border:none;"></td>
<td width="173" style="border:none;"></td>
<td width="543" style="border:none;"></td>   </tr> </table>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\jkarthi\11-26858-1\task4878519\26858-1-mm.htm',USER='105429',CD='Sep 22 09:13 2011' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words &#147;may,&#148; &#147;will,&#148; &#147;would,&#148; &#147;could,&#148; &#147;should,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;projects,&#148; &#147;potential,&#148; &#147;expects,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;intends,&#148; &#147;continues,&#148; &#147;forecast,&#148; &#147;designed,&#148; &#147;goal,&#148; or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form&nbsp;10-K and other periodic and current filings that have been filed with the Securities and Exchange Commission and are available at www.sec.gov.&#160; Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Contact for Cyclacel Pharmaceuticals,&nbsp;Inc.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Investors/Media: Corey Sohmer, (908) 517-7330, csohmer@cyclacel.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#169; Copyright 2011 Cyclacel Pharmaceuticals,&nbsp;Inc.&#160; All Rights Reserved.&#160; The Cyclacel logo and Cyclacel</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font><font size="2" style="font-size:10.0pt;">&#160;are trademarks of Cyclacel Pharmaceuticals,&nbsp;Inc.&#160; Numoisyn</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font><font size="2" style="font-size:10.0pt;">&#160;and Xclair</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font><font size="2" style="font-size:10.0pt;">&#160;are trademarks of Sinclair Pharma plc.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="PB_2_055547_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\jkarthi\11-26858-1\task4878519\26858-1-mm.htm',USER='105429',CD='Sep 22 09:13 2011' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g268581mmi001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g268581mmi001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!!`*X#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^LG7?$6G
M^'[827<A,C#]W"G+O_@/>CQ%KL/A_29+R4!I#\L4>?ON>@^G<UYYI^C'54F\
M3^*;EDLC\P4\-+Z`>B]@!UKLP^'4U[2I\/XM]D<&+Q<H/V5+66_DEW87'B_Q
M/XCG:'28)88\_=MERP_WG[?I56?PCXCGP^HW$49/(^UW@S_,UIKJ6N:_`T.@
MP1Z1HL7!ER(P!ZEOZ#\36'/IOAZ)C]L\1RW,_P#$;>W+C_OICS7JT_<]V"4?
M))R?SL>%57/[TVY>;:BODGN2)X7\268,M@WF!>2;*Z!/Y`@U9T_QUK^C7'V>
M_#7*J?FBN5*R#_@77\\U0BTO2)G4Z7XB$4_\*W430\_[XR!5RYU*^LV33O%=
MFUY;,,QS$@RJ/[T<@^\/8U<DJFDTI?*S^5]_P(@W2]ZG)Q\[J4?G;;\3TS0O
M$>G^(+<R6DF)%'[R%^'3\.X]ZUJ\GFM;;X=6,OC*>[>\T^.,?9X8DVR2^9@*
M&SP!SG\*Z_P#XXM/'WA]M4M;:6V:.8P2PR'=M<`'@]QAASQ7A8F%.-2U)W1]
M-A)UITKUE9_GYG4T445@=(4444`%%%%`!1110`4444`%%%%`!1110!YYJ<)\
M7?$!=.8DZ?IJYE`Z$\9'XG`^@-)J/E^*-?N%N)/*\/:,/WFTX#L!R!CZ8^@]
MZF\(3"'P_KVOL?WDTLLFX\D!02/U)J*UTTGPOH&C<@ZK/]HNCW9`-[?IM%>O
M?DERK3ET7EI>3]3P;<\>9Z\_O/SUM%>A4NMNK6D6HZN9+31`=FGZ9;##S^G`
M]?\`..\C"ZLHU\NQ\/:%$>46^8/,1[]36JR2WFIR7<`5;B29K#3B5RMM&F?,
ME`Z9X./P%=!8^'=,L5)%JDTS<R3SCS)'/<EC43KQ@DG]W]?BW>[-*>%E4DVG
M\_Z_!*R2MN<!=Q&2U,^IZ-IM_9#[][H[!7C]R!_44]9M)\(:`^IZ]?I>^&)V
M06D;P%W$C$D?+CY>`<XX-==?Z3I-AJ=I=6T)MM0E9EACM\HEPP0ML?`(`P#R
M:6Q\/&[FGOM9#R_;88?,TF=UGM;5T'/E@KCKWK*KC+PY8?U_7=6]#>A@.6IS
MU/Z]=KKR=_4Y?1O#_B?5_%.LGQ#=6FH>"[Z+-G:$`J4)!CPN`5*KU/K^8[K1
MM#TSP]IR:?I-E%:6JDD1QCN>I)ZD^YK0````&`.@K+\0^(-.\+Z)<:MJDQCM
M80,[1EF)X"J.Y)K@/3-2BN`MO$WC[58%OK#P=9V]FXWQQ7]_LGD7M\H4A#[&
MKDGC.^TSQCI&CZWID=G:ZM;@V]PLN_9<@#="QQC/8$=<C\`#LZ*Y7Q1XLGTG
M6='T+2K1+W5M2E.(W8JL,*_?E8CL.WKS5/5_'ES_`,)#-X=\,:,^LZK;J&NF
M,PAM[;/0.YSEO8?XT`=M17+Z1JGBT/=#7]$L+>&.!I8[BTO#(&8?P%2H(XSS
MTXJ7P)XEE\7^#;#79K9+:2YWYB1BP7:[+U/^[F@#HZ*HZSJEOHFBWNJ71Q!:
M0M,_N%&<?4]*Y7X>^/+GQ?\`;[;4],&F:C:B*7R-Y;=#*@9&Y`_SB@#N**YC
MQ9XTM_#,EI8PV<^I:S?$BTT^W(#R8ZLQ/"J/4_T.*ECJWCYKZV.H>&-,CLI9
M5640ZCNE@0GECE<-@<X'I0!V5%><MXW\5ZCXOUW1-!T#3KE-)DC1Y;B\,9;>
MN1Q@^AJWXD\9Z]X3^'\NO:KI%FNH1SK']EBN"T>UF`!W8Z_A0!W=4#K>FK(R
M->1*5)4Y.!D=?YU<AD\V".0C!=0V/J*PY/!^E2SRR21L?,(+#/)QP,GV&0/K
MWH`QO#=FTG@#5-/&3(KW,)QU)Y%7+,H\?A"]!_=B$P\=`S1<#\UQ5C2Q_9?B
MS4]/?B*^Q>P'L6Z2#ZYP:CMK(1K>>'G?RGC?[5I\GHN[<,?[C<$>A'K7H3G>
M4GWU^35G]QY<*?+&*[:?.+NOOM^1-ID8@FM-_!AGN8&]`SOO7\P!^==%6#&S
M7)EF$'^D85+ZS!P0PZ.A]?0]QCN*O6UXS#8DT4V/[Y\N0?[RXZ_E7-53D[G7
M1DHJW]=BXEO%'-+,D8627'F,.K8&!G\*DK.>_*2@/)'N'2"#]X['^@_SFKZM
MN49&UL`E<]*R<6MS>,U+8=7F7QC:.)/"4UZ&_LR/7(6NC_"!S@M[=:]-JAK6
MC:?X@TFXTO4[=;BTG7:Z-^A![$'D&I*+X((R.17-^.O#<'BCPI=V4C^5/$/M
M%K<#[T,R<JP_D?8FL*#X>^(--B2STCX@:I;:<@VI!/;13NB]@KMR`.G2NVCL
MW724LI;F29Q`(FGD`W.=N"QQQD]:`//OA#%/KVG3^.=7E2XU?5/W`95PL,,9
MVA%';+*6/KQ3?@Z\8_X2Z"?(U1=<G:Z#GYR#]TGVX;]:ZWP3X67P9X4M=#6[
M-V+<N?.,>S=N8MTR?7UK.UWX>VVI:Z=?TG5+S0]99-DMS9D%9@.GF(>&[?D*
M`.IU'_D&7?\`UQ?_`-!-<3\%/^22:)_VV_\`1SUJZ)X9UVRDN7UCQ;=:N)H&
MA6-K6.%$SCYL+U/'KW-<UH_PS\5:!I4.F:7\1+BWLH,^7$-+B;;DECR6)ZDF
M@"/XR:[9QQZ+X9NII([;4;I9;\Q1M(PMHV!(VJ"?F;`_`UBWWCGP]%\5/#VN
MZ//.(;J,Z7J"R6DL*A"1Y3990.&_05Z1I_A/[+XUO?$]U?M=W,]I':0(8@H@
MC7EL')SN;YNV*L>,?#%OXP\,7>BW$IA$VTI,J[C$ZD$,!D>GKWH`XZ)EB_:-
MG%\5!ET,"PW#KAP6"^_#_A7IU<IKG@2S\2:5IL6I7=P-4T]%\C5+4^5,C@`%
MAUZD9(YJMI_A'Q/;:A;RWGCZ_N[.&17-O]CB0R`$':SCD@XP>E`'$Z1:>*+K
MXJ^._P#A&]5L;';/;^=]JMS+O^0XQCICG\ZO_%N'5;?X+SQZW=P7=^+F+S)K
M>/RT8>9QA?IBM>Z^'.MQ^*=7UO1/&<VE'5'1YH5L$E'RC`Y9OKV'6K>L^`M1
M\1>`YO#FL>)9+NYDG67[>;15(`((78I`[=<]Z`.SL_\`CR@_ZYK_`"J:N(TG
MPEXNL-1M9KOQ_/>VD+@R6K:;$@D4?P[@<CZUV]`&5KNER:A;Q36CK'J%H_FV
MTAZ;NZG_`&6'!JO%)!XDL%=2]GJ-J_3_`):6TO<$=P?R85NUE:CHPNKE;ZSG
M-GJ*+M$RC(<?W77^(?J.U;0GHHMVML_ZZ'/4IN[E%7ONN_FO,IR7$;31IJZG
M3[]/ECNXVQ')_NL>,'^ZWZ]:O-!?.H#K8WBXX:12A(_)A55M8EMD,.NZ>T2D
M8,\*&:!Q[X&5^C#\:;!'X<F&^SNX(PW:WNS'^BL,5HT[:K]49)INR>OGH_FN
MOK8MB#4%C(\RSL8P,L84W$?B<`?B#5:VO($D:#1XVOIG8>?=.Y*#']Y^Y]%7
M]*CN(_#-OB2\NK>0CI]IN3+^C$Y_*GKK<MV@AT/3I)5'`GF0PP*/;(RWT`_&
MCE;6B_1?\'[PYDG9O7RU?R73[C>HK/TW3YK0R3W=Y)=74V-['Y44#HJ+T`Y^
MI[FM"N:22=D[G7%MJ[5@HHHI%!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`5YIXU_P"/F3_?HHKMP'\4\W-/X`WP1_Q]+_UT_I7IM%%/'_Q0RO\`@!11
B17">D%%%%`!1110`4444`%%%%`!1110`4444`%%%%`'_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g268581mmi002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g268581mmi002.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MP``+"``:`D`!`1$`_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+
M_\0`M1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$(
M(T*QP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%56
M5UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI
MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W
M^/GZ_]H`"`$!```_`/?Z****************R]=O9[&RCDMV57>54W,,X!IN
ME7T\][>6DTB3B`KMF1<!LCH>V:UJIZI<R6>EW-Q%CS(T++D9&:S=.U&\;4+:
MWFE2X2>W\TE4VF,^AQVK>H/2L#0=2N=0D9I[V$D%A]G5`&P.ASFM^F2N8XG=
M5+%5)"CO[5D:#?SZBC32W<3'!W6ZIAHSGUK:IDSF."1U4LRJ2%'?CI63H-_/
MJ,9FENXG)'S0*F#&<ULT445E:Y>W%G%;"W=4::=8RS+G`-+I-[<7%Q>6\[+*
M+=PJS(N`V1T^HK4JEJUS)::5<7$)`DC3*Y&:AT6YEN[7S9;R*X)"DB-0/+..
M0:TZH:U=RV.D3W$!`D0#!(R.H%6K9VDM8I&^\R`GZD5+67K]]/I^F>?;LJOY
MBKEAD8-6=.D:6UWM=QW66.)(UP/I5NJ6JW;6.G2S)CS.%C![L3@5'HM[+>V)
M-QC[1$[1R@#'(-:-5M0N'M=/GGC3>\:%@OK531+J6\M?/DO(KC<`=J)M,9[@
MUJ56U"9[?3KF:,@/'&S+D9Y`JCH5Y-?6_G37D4S%03&B`&,^AK7HHHHHHHHH
MHHHHHHHHHHHHHHHHHHHHHHHHK-UO3Y=2M(H8MF5E5VWG@@=:O0V\-LFR")(U
MZX1<"I*J:I;/>:9<6\14/(A4%NE4-,TFXTR]#QF/R)8E$RYY#@=1[5M4=JQ-
M$TZ]TW,4T=L8RS-YBD[^>W3I6W2/NV-LQNQQGIFL6PTN[76'U&[%O$QCV;(,
MX8^IS6W37W;&V8WX.W/3-8^GZ7=)J\FHW0MXF9-GEP9P?<YK:HHHK,UG3I-1
MCMD39MCG5W#GJO<4ND6,^FI-;.R-;ART!!^8`]C6E5/5+62]TRXMHBH>1<`M
MTIFDP7-M:B&XBMTV*JJ823NP.IXZU?JCK%G)?Z5/;1%0[@8+'CJ#3]/6ZCM5
MCNUB5D`5?+8D$`=\U;K-UVPFU+3O(@*!]ZM\YP.*LV2SK!BXBAB?)^6$_+C\
MJLUFZKI\VHR6L:R;((Y/,D(.&R.F*9INFSZ?J%VWF^9;S88%VR^[OGBM6HY_
M-\A_("&7'RA_NY]\5EZ1I<]K>75Y<"&-Y\#RH<[5QW^M;%5[^!KG3[B!"`\D
M;*,],D54T:UNK*V$%Q%;J$4`-$22WUXK3HHHHHHHHHHHHHHHHJ"XO+>TV^?*
MJ;NF>]0?VQI__/TGZT?VQI__`#])^M']L:?_`,_2?K1_;&G_`//TGZT?VQI_
M_/TGZT?VQI__`#])^M']L:?_`,_2?K1_;&G_`//TGZT?VQI__/TGZT?VQI__
M`#])^M']L:?_`,_2?K1_;&G_`//TGZT?VQI__/TGZT?VQI__`#])^M']L:?_
M`,_2?K1_;&G_`//TGZT?VQI__/TGZT?VQI__`#])^M']L:?_`,_2?K1_;&G_
M`//TGZT?VQI__/TGZT?VQI__`#])^M']L:?_`,_2?K1_;&G_`//TGZT?VQI_
M_/TGZT?VQI__`#])^M']L:?_`,_2?K1_;&G_`//TGZT?VQI__/TGZT?VQI__
M`#])^M']L:?_`,_2?K1_;&G_`//TGZT?VQI__/TGZT?VQI__`#])^M']L:?_
M`,_2?K1_;&G_`//TGZT?VQI__/TGZT?VQI__`#])^M']L:?_`,_2?K1_;&G_
M`//TGZT?VQI__/TGZT?VQI__`#])^M']L:?_`,_2?K1_;&G_`//TGZT?VQI_
M_/TGZT?VQI__`#])^M']L:?_`,_2?K1_;&G_`//TGZT?VQI__/TGZT?VQI__
M`#])^M']L:?_`,_2?K1_;&G_`//TGZT?VQI__/TGZT?VQI__`#])^M']L:?_
M`,_2?K1_;&G_`//TGZT?VQI__/TGZT?VQI__`#])^M']L:?_`,_2?K1_;&G_
M`//TGZT?VQI__/TGZT?VQI__`#])^M']L:?_`,_2?K1_;&G_`//TGZT?VQI_
M_/TGZT?VQI__`#])^M']L:?_`,_2?K1_;&G_`//TGZT?VQI__/TGZT?VQI__
M`#])^M36]]:W3E()E=@,D#TJQ1@>E&!Z48'I1@>E&!Z48'I1@>E&!Z48'I1@
M>E&!Z48'I1@>E&!Z48'I1@>E&!Z48'I1@>E&!Z48'I1@>E&!Z48'I1@>E&!Z
M48'I1@>E&!Z48'I1@>E&!Z48'I1@>E&!Z48'I1@>E&!Z48'I1@>E&!Z48'I1
M@>E&!Z48'I1@>E&!Z48'I1@>E&!Z48'I1@>E&!Z48'I1@>E&!Z48'I1@>E&!
CZ48'I1@>E&!Z48'I1@>E&!Z48'I1@>E&!Z48'I1@>E%?_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
